Lucid Diligence Brief: AstraZeneca buys remaining China rights to AbelZeta’s GPC3-armored CAR-T
Lucid Diligence Brief: AstraZeneca buys remaining China rights to AbelZeta’s…
AI in Healthcare and Digital Health Today—January 19, 2026
This week's AI in Healthcare and Digital Health update highlights rapid…
Lucid Diligence Brief: Signet Therapeutics RMB 80 million Series A for organoids + AI in oncology
Lucid Diligence Brief: Signet Therapeutics RMB 80 million Series A for…
Lucid Diligence Brief: AstraZeneca to acquire Modella AI
Lucid Diligence Brief: AstraZeneca to acquire Modella AI Professional audiences…
Lucid Diligence Brief: Cytotheryx $60 million Series A in liver cell therapy
Lucid Diligence Brief: Cytotheryx $60 million Series A in liver cell therapy…
Lucid Diligence Brief: Ocugen preliminary Phase 2 data in geographic atrophy
Lucid Diligence Brief: Ocugen preliminary Phase 2 data in geographic atrophy…
Lucid Diligence Brief: Caldera Therapeutics launches with $112.5 million in IBD
Lucid Diligence Brief: Caldera Therapeutics launches with $112.5 million in……
Lucid Diligence Brief: Novartis and SciNeuro BBB “brain-shuttle” Alzheimer’s deal
Lucid Diligence Brief: Novartis and SciNeuro BBB “brain-shuttle” Alzheimer’s…
Lucid Diligence Brief: Mirador Therapeutics $250 million Series B in immuno-fibrotic disease space
Lucid Diligence Brief: Mirador Therapeutics $250 million Series B in…
AI in Healthcare and Digital Health Video Recap —January 12, 2026
Here’s your AI in Healthcare and Digital Health video brief covering recent…
AI in Healthcare and Digital Health Today—January 12, 2026
This AI in Healthcare and Digital Health roundup highlights accelerating…
Lucid Diligence Brief: Chai Discovery and Eli Lilly biologics AI collaboration
Lucid Diligence Brief: Chai Discovery and Eli Lilly biologics AI collaboration…